Cibus, Inc. (NASDAQ: CBUS) is a Healthcare company (Biotechnology) with a market capitalization of $106M. The Maz Rating grades it against the other companies in its sector.
Cibus, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.39, Cibus, Inc. trades at 22.7x sales. Over the last twelve months it generated about $5M of revenue and a net loss of $118M. It runs a gross margin of 47.9%, an operating margin of -1125.6% and a net margin of -2131.4%. It shows return on equity of -581.5%, return on invested capital of -17.5% and a free cash flow yield of -41.8%. On the balance sheet: a debt-to-equity ratio of -5.62 and a current ratio of 0.95. Over the past 52 weeks the share price ranged from $1.02 to $4.19, with a beta of 1.57.
Cibus, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 3 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.